Heron Therapeutics Inc (NASDAQ:HRTX) – Stock analysts at Jefferies Financial Group upped their FY2018 earnings per share (EPS) estimates for Heron Therapeutics in a report released on Monday, January 7th. Jefferies Financial Group analyst B. Amin now expects that the biotechnology company will post earnings of ($2.29) per share for the year, up from their prior forecast of ($2.34). Jefferies Financial Group also issued estimates for Heron Therapeutics’ Q4 2018 earnings at ($0.45) EPS, Q2 2019 earnings at ($0.43) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.05) EPS and FY2019 earnings at ($1.13) EPS.

Heron Therapeutics (NASDAQ:HRTX) last announced its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.05). The business had revenue of $19.79 million during the quarter, compared to the consensus estimate of $19.84 million. Heron Therapeutics had a negative return on equity of 72.23% and a negative net margin of 326.79%. The company’s revenue was up 130.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.77) earnings per share.

A number of other brokerages have also weighed in on HRTX. Stifel Nicolaus assumed coverage on shares of Heron Therapeutics in a report on Thursday, September 13th. They issued a “buy” rating and a $55.00 price objective for the company. Cantor Fitzgerald set a $50.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, September 21st. BidaskClub lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 22nd. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. Finally, ValuEngine upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $52.09.

Shares of HRTX opened at $25.34 on Thursday. The company has a market capitalization of $2.03 billion, a PE ratio of 6.94 and a beta of 1.49. Heron Therapeutics has a fifty-two week low of $18.65 and a fifty-two week high of $42.90.

A number of large investors have recently bought and sold shares of HRTX. Cubist Systematic Strategies LLC bought a new stake in Heron Therapeutics during the 2nd quarter valued at $151,000. Jefferies Group LLC bought a new position in Heron Therapeutics in the 3rd quarter worth $202,000. Verition Fund Management LLC bought a new position in Heron Therapeutics in the 3rd quarter worth $208,000. Pacer Advisors Inc. bought a new position in Heron Therapeutics in the 3rd quarter worth $223,000. Finally, Public Employees Retirement Association of Colorado bought a new position in Heron Therapeutics in the 3rd quarter worth $224,000.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also: What is Compound Interest?

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.